AAAAAA

   
Results: 1-9 |
Results: 9
EARLY CLINICAL-EXPERIENCE WITH SUBCUTANEOUS NARATRIPTAN IN THE ACUTE TREATMENT OF MIGRAINE - A DOSE-RANGING STUDY
Authors: DAHLOF C HOGENHUIS L OLESEN J PETIT H RIBBAT J SCHOENEN J BOSWELL D FUSEAU E HASSANI H WINTER P
Citation: C. Dahlof et al., EARLY CLINICAL-EXPERIENCE WITH SUBCUTANEOUS NARATRIPTAN IN THE ACUTE TREATMENT OF MIGRAINE - A DOSE-RANGING STUDY, European journal of neurology, 5(5), 1998, pp. 469-477
COMPARATIVE CLINICAL PHARMACOKINETICS OF SINGLE DOSES OF SUMATRIPTAN FOLLOWING SUBCUTANEOUS, ORAL, RECTAL AND INTRANASAL ADMINISTRATION
Authors: DUQUESNOY C MAMET JP SUMNER D FUSEAU E
Citation: C. Duquesnoy et al., COMPARATIVE CLINICAL PHARMACOKINETICS OF SINGLE DOSES OF SUMATRIPTAN FOLLOWING SUBCUTANEOUS, ORAL, RECTAL AND INTRANASAL ADMINISTRATION, European journal of pharmaceutical sciences, 6(2), 1998, pp. 99-104
ACUTE TREATMENT OF MIGRAINE WITH ORAL NARATRIPTAN - THE CONCENTRATION-EFFICACY RELATIONSHIP
Authors: FUSEAU E WEBSTER C ASGHARNEJAD M HUFFMAN C SAMBOL N LIU CY
Citation: E. Fuseau et al., ACUTE TREATMENT OF MIGRAINE WITH ORAL NARATRIPTAN - THE CONCENTRATION-EFFICACY RELATIONSHIP, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 58-58
SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUMATRIPTAN IN HEALTHY-SUBJECTS FOLLOWING ASCENDING SINGLE INTRANASAL DOSES AND MULTIPLE INTRANASAL DOSES
Authors: MOORE KHP HUSSEY EK SHAW S FUSEAU E DUQUESNOY C PAKES GE
Citation: Khp. Moore et al., SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUMATRIPTAN IN HEALTHY-SUBJECTS FOLLOWING ASCENDING SINGLE INTRANASAL DOSES AND MULTIPLE INTRANASAL DOSES, Cephalalgia, 17(4), 1997, pp. 541-550
MIXED EFFECT MODELING OF SUMATRIPTAN PHARMACOKINETICS DURING DRUG DEVELOPMENT .1. INTERSPECIES ALLOMETRIC SCALING
Authors: COSSON VF FUSEAU E EFTHYMIOPOULOS C BYE A
Citation: Vf. Cosson et al., MIXED EFFECT MODELING OF SUMATRIPTAN PHARMACOKINETICS DURING DRUG DEVELOPMENT .1. INTERSPECIES ALLOMETRIC SCALING, Journal of pharmacokinetics and biopharmaceutics, 25(2), 1997, pp. 149-167
ORAL NARATRIPTAN TABLETS (2.5 MG 10 MG) EXHIBIT DOSE-PROPORTIONAL PHARMACOKINETICS
Authors: KEMPSFORD RD BAILLE P FUSEAU E
Citation: Rd. Kempsford et al., ORAL NARATRIPTAN TABLETS (2.5 MG 10 MG) EXHIBIT DOSE-PROPORTIONAL PHARMACOKINETICS, Neurology, 48(3), 1997, pp. 1128-1128
ABSOLUTE BIOAVAILABILITY OF ORAL NARATRIPTAN
Authors: FUSEAU E BAILLE P KEMPSFORD RD
Citation: E. Fuseau et al., ABSOLUTE BIOAVAILABILITY OF ORAL NARATRIPTAN, Neurology, 48(3), 1997, pp. 1129-1129
PLASMA AND SKIN SUCTION-BLISTER-FLUID PHARMACOKINETICS AND TIME-COURSE OF THE EFFECTS OF ORAL MIZOLASTINE
Authors: CHOSIDOW O DUBRUC C DANJOU P FUSEAU E ESPAGNE E BIANCHETTI G THENOT JP HERSON S ROSENZWEIG P REVUZ J
Citation: O. Chosidow et al., PLASMA AND SKIN SUCTION-BLISTER-FLUID PHARMACOKINETICS AND TIME-COURSE OF THE EFFECTS OF ORAL MIZOLASTINE, European Journal of Clinical Pharmacology, 50(4), 1996, pp. 327-333
REDUCTION OF HYPERGLYCEMIA AFTER ORAL GLUCOSE-LOAD BY THE NEW ALPHA(2)-ADRENERGIC RECEPTOR ANTAGONIST SL84.0418 IN HEALTHY-SUBJECTS
Authors: BERLIN I ROSENZWEIG P CHALON S FUSEAU E LANDAULT C CESSELIN F BLACKER C PUECH AJ
Citation: I. Berlin et al., REDUCTION OF HYPERGLYCEMIA AFTER ORAL GLUCOSE-LOAD BY THE NEW ALPHA(2)-ADRENERGIC RECEPTOR ANTAGONIST SL84.0418 IN HEALTHY-SUBJECTS, Clinical pharmacology and therapeutics, 55(3), 1994, pp. 338-345
Risultati: 1-9 |